Headquartered in Texas, MicroTransponder Inc. is at the forefront of neurological innovation with the development of the Paired Vagus Nerve Stimulation (Paired VNS™) Platform. This revolutionary technology stems from decades of cutting-edge neuroscience research, designed to address the unmet needs of patients suffering from chronic neurological conditions.
The Vivistim® System: A Breakthrough for Post-Stroke Rehabilitation
The first major advancement on the Paired VNS platform is the Vivistim® System, which offers a novel treatment option for individuals suffering from post-stroke upper limb impairment. Approved by the U.S. Food and Drug Administration (FDA), the Vivistim® System leverages the power of Paired VNS to help stroke survivors regain motor function in their upper limbs. This approval marks a significant milestone for MicroTransponder, underscoring the company’s commitment to developing life-changing solutions for patients with neurological challenges.
Commitment to Expanding Access and Future Innovations
MicroTransponder is dedicated to making the Vivistim® System accessible to all stroke survivors. By collaborating with healthcare providers and medical institutions, the company is working to ensure that patients from various backgrounds can benefit from this groundbreaking technology.
Looking beyond stroke rehabilitation, MicroTransponder is also exploring the potential of Paired VNS™ for treating other chronic neurological conditions, such as traumatic brain injury, chronic pain, and tinnitus. With ongoing research and development, the company aims to push the boundaries of neurological therapy, offering new hope to millions of individuals affected by neurological impairments worldwide.